Showing results (181-190 of 246) with videos related to

Sort By:
Pageof 25
Lancet (London, England)|August 6, 2026
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trialScott T Tagawa, Oliver Sartor, Josep M Piulats, et al.
Nature Communications|November 22, 2014
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancerDimple Chakravarty, Andrea Sboner, Sujit S Nair, et al.
Cancer Research|January 14, 2026
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader MoleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Cancer Discovery|January 10, 2024
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA MethylationGian Marco Franceschini, Orsetta Quaini, Kei Mizuno, et al.
Nature|November 26, 2025
NSD2 targeting reverses plasticity and drug resistance in prostate cancerJia J Li, Alessandro Vasciaveo, Dimitris Karagiannis, et al.
Nature Cancer|July 14, 2021
Accelerating precision medicine in metastatic prostate cancerJoaquin Mateo, Rana McKay, Wassim Abida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2026
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)Rana R McKay, Karla V Ballman, Pamela J Atherton, et al.
Cancer Discovery|March 24, 2017
Personalized In Vitro and In Vivo Cancer Models to Guide Precision MedicineChantal Pauli, Benjamin D Hopkins, Davide Prandi, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2012
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer riskFrancesca Demichelis, Sunita R Setlur, Samprit Banerjee, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
Pageof 25